Abstract
Background

Soon after its discovery in 1995, IL-24 (then called mda-7) has been described as a potential therapeutic option for cancer (reviewed in
). First thought to be a tumour suppressor, Zhang et al. [5] clarified already in 2000 that mda-7/IL-24 is in fact a secreted protein, further substantiated by the identification of the specific receptor complexes [6, 7] , which led to the re-naming of mda-7 to IL-24 cytokine. Nevertheless, around 100 publications, the majority of which come from three groups at Columbia University, the M. D [2, 3, 10] .
. Anderson Cancer Center in Texas and Introgen Therapeutics, have suggested that IL-24 has the ability to selectively and efficiently kill cancer cells in vitro and in vivo. These astonishing properties led to the rapid development of a therapeutic regimen by which a modified adenovirus delivers IL-24 to cancer patients (INGN-
241
IL-24: a normal cytokine?
IL-24, together with [11] [12] [13] . Although sequence homologies within this group do not exceed 25%, there is some conservation of structural features, namely the presence of six to seven ␣-helices in all family members [11, 13, 14] [10, 39] [39] . Thirdly (Fig. 1) illustrates and summarizes the effects that the described different forms and delivery modes of IL-24 might have. [42, 43] [44] [45] [46] , however, a useful but still lacking control for the specificity of IL-24 and for synergistic effects of the Ad backbone would be an adenovirus expressing IL-20, as IL-20 is a related cytokine that uses the same receptor complexes. 
. Taken together, IL-24 has been suggested to distinguish between cancer and normal cells and by doing so it can kill the cancer cells in a receptor-independent ordependent fashion, either through direct interaction or via secondary bystander effects, respectively. In this context, we recently found that the melanoma cell lines used in the above study (Wm35, Mewo, and A375) [39] hardly expressed IL-24 receptors and consequently did not show phosphorylation of STAT3 following IL-24 treatment [33]. Hence, the receptor-mediated killing of these cells by IL-24 or possible bystander effects are difficult to reconcile with the fact that sufficient amounts of the three possible receptor chains were not present on such cells. In the same study, we further investigated different forms and modes of IL-24 delivery to melanoma cells but could not identify any condition under which this cytokine killed melanoma cells [33]. To substantiate our data, we have used four different ways of treating a panel of melanoma cell lines with IL-24: (1) by GST-IL-24 fusion protein (previously shown to kill cancer cells [36]); (2) by IL-24 secreted from transfected Hek cells, also previously published to drive cancer cells selectively and efficiently into apoptosis
Adenovirus: contributions to IL-24 oncolytic effects?
In order to improve IL-24 delivery to cancer cells, various replicationdeficient adenoviruses have been developed that all aim at selectively transducing target cells. Third generation adenoviruses driven by promoters, which only function in cancer cells have boosted the selectivity of IL-24 delivery even further
. Over the past decade, many studies have claimed that intracellular over-expression of an adenovirus encoded IL-24 (Ad-IL-24) drives a multitude of different cancer cells and types into apoptosis or regression, respectively. There is evidence that the combination of IL-24 with an adenoviral backbone has the desired oncolytic effects while the empty vector control does not
